Universal tolerance of nab-paclitaxel for gynecologic malignancies in patients with prior taxane hypersensitivity reactions

OBJECTIVE: To report on the incidence of nab-paclitaxel hypersensitivity reactions (HSRs) in patients with prior taxane HSR. METHODS: From 2005 to 2015, all patients who received nab-paclitaxel for a gynecologic malignancy were identified. Chart abstraction included pathology, prior therapy, indicat...

Descripción completa

Detalles Bibliográficos
Autores principales: Maurer, Kathryn, Michener, Chad, Mahdi, Haider, Rose, Peter G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5447141/
https://www.ncbi.nlm.nih.gov/pubmed/28541630
http://dx.doi.org/10.3802/jgo.2017.28.e38

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5447141/
https://www.ncbi.nlm.nih.gov/pubmed/28541630
http://dx.doi.org/10.3802/jgo.2017.28.e38

Ejemplares similares